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1. Introduction 
Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer-related death in 
developed countries, is a lethal disease with an overall 5-year survival rate of <5% [1]. Due to the 
paucity of early symptoms, along with aggressive tumor behavior, less than 20% of patients present 
localized and resectable diseases at the time of diagnosis, and standard therapies only have a limited 
beneficial impact on advanced-stage patients [2]. Currently, attempts are being made to identify 
novel biomarkers to diagnose and predict PDAC outcome. 
We have previously described lpha-enolase (ENOA) as a tumor-associated antigen (TAA) in 
PDAC [3]. ENOA is a moonlighting protein that works both as a glycolytic enzyme and as a 
membrane plasminogen receptor, thus promoting tumor proliferation, spreading and metastasis [4, 
5]. In particular, a fraction of PDAC patients specifically produce autoantibodies against two Ser
419
 
phosphorylated isoforms of ENOA (ENOA1,2), which are over-expressed in PDAC [3, 4, 6, 7]. The 
detection of autoantibodies against ENOA1,2 positively complements the diagnostic performance 
of the commonly used serum marker CA19.9. Moreover, patients with autoantibodies against 
ENOA1,2 have a more favorable clinical course, with a longer progression-free and overall survival 
rate upon gemcitabine treatment [3]. 
A variety of post-translational modifications of naturally processed peptides displayed by MHC 
class I or II molecules have recently been described [8]. Among the post-translationally modified 
peptides identified to date, phosphopeptides are of particular interest, as deregulated 
phosphorylation is one of the major hallmarks of malignant transformation. T cell discrimination of 
phosphopeptides versus their unphosphorylated counterparts has also been observed, indicating that 
phosphorylation can influence peptide immunogenicity [9, 10, 11, 12]. Depending on the position 
within the peptide, phosphorylation tends to stabilize the complex, without greatly altering the 
peptide-binding mode. 
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The prognostic value of autoantibodies to ENOA1,2, together with the ability of ENOA to induce a 
specific CD4
+
 T cell response, led us to investigate whether the ability to produce autoantibodies 
against ENOA1,2, in PDAC patients, is associated with specific HLA-DRB1 alleles. Here, we 
demonstrate that expression of the HLA-DRB1*08 allele is greater in PDAC patients with 
autoantibodies to ENOA1,2 compared to healthy controls or patients lacking these antibodies. We 
found that a bioinformatically-predicted Ser
419
phosphorylated-ENOA peptide, which binds with 
high affinity to the HLA-DR8 molecule coded by HLA-DRB1*08:01 or *08:04 alleles, was able to 
activate in vitro proliferation of specific CD4
+
 T cell clones derived from a HLA-DRB1*08:01 
donor.  
2. Materials and Methods 
2.1. Human samples. The study was approved by the Ethical Committee of Azienda Ospedaliera 
Universitaria Città della Salute e della Scienza di Torino, Turin and was in accordance with the 
1964 Helsinki declaration. Serum samples and PBMCs were isolated from venous blood at the time 
of diagnosis, with the informed consent of the PDAC patients, and stored at 80°C until use. De-
identified numeric specimen codes were used to protect the identity of the individuals. Diagnosis of 
PDAC was consistently confirmed by histological or cytological analysis. A total of 113 Italian 
PDAC patients, with clinical features described in Supplementary Table 1, were screened for 
reactivity against ENOA isoforms by two-dimensional electrophoresis Western blot (2-DE WB), as 
described previously [3]. Briefly, cells (10
7
) from the CF-PAC-1 cell line (ECACC ref. No. 
91112501) were solubilized, subjected to 2DE and electro-transferred onto a nitrocellulose 
membrane (GE Healthcare Bio-Sciences, Uppsala, Sweden). Sera were individually tested on 2DE 
maps at a working dilution of 0.1 mg/ml IgG for 4 h, followed by incubation with horseradish 
peroxidase (HRP)-conjugated rabbit anti-human IgG (90 minutes, 1:1000; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) as a secondary antibody. Immunodetection was 
accomplished by ECL PLUS (Enhanced Chemiluminescence, GE Healthcare Bio-Sciences) and the 
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resulting chemifluorescent signals were scanned with “ProXPRESS 2D” (PerkinElmer). The 
volume of ENOA1,2 spots recognized by autoantibodies was calculated after background 
subtraction using “ProFinder 2D” (PerkinElmer) software. Out of 113 patients, 104 were evaluable 
for ENOA1,2 reactivity and 36 of them (35%) were positive for the presence of ENOA1,2 
autoantibodies. Their genomic DNA was obtained from PBMCs, using a NucleoSpin
®
 Blood kit 
(Macherey-Nagel Gmbh & Co. KG) on an automatic workstation Biomeck 2000 (Beckman-
Coulter, Inc., Milano, Italy). The control group was composed of about 261,000 Italian healthy bone 
marrow donors (listed in the Italian Bone Marrow Donor Registry-IBMDR), previously typed with 
serological or molecular techniques [13]. To generate T cell clones and autologous EBV-B cell 
lines, a HLA-DRB1*08 healthy donor was selected from the IBMDR and enrolled after written 
informed consent. 
2.2. HLA typing. Low resolution HLA-DRB1 typing of PDAC patients was performed using a 
LABType
®
 SSO kit (RSSO2B1, One Lambda-Thermo Fisher Scientific, Inc., CA, USA), based on 
the SSO-reverse principle, on a Luminex
®
 100™ instrument. High resolution of HLA-DRB1*08 
positive samples was obtained using the Sequence Based Typing (SBT) method with an Allele 
SEQR HLA-DRB1 Core kit (Abbott Laboratories, Abbott Park, Illinois, USA) on an ABI PRISM 
3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). 
2.3. Prediction of possible HLA-DRB1 ligands of the ENOA C-terminus. Possible HLA-DRB1 
ligands of the C-terminus region of ENOA
410-432
 were predicted using the bioinformatics tool IEDB 
(http://tools.immuneepitope.org/mhcii/) [14]. Based on the availability of predictors and previously 
observed predictive performance, IEDB uses the best possible method for predicting binding of a 
given MHC molecule from the currently implemented MHC class II binding prediction methods, 
namely: Consensus method, Combinatorial library, NN-align (netMHCII-2.2), SMM-align 
(netMHCII-1.1), Sturniolo, and NetMHCIIpan. For each predicted binding peptide, a median 
percentile rank of each applied method was generated by comparing the score of the peptide against 
the scores of five million random 15mers selected from the SWISSPROT database. A numerically 
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low percentile rank indicates a high affinity. Predictions were further confirmed by means of other 
publicly available methods of prediction (NetMHCII, http://www.cbs.dtu.dk/services/NetMHCII/; 
HLAPred, http://www.imtech.res.in/raghava/hlapred/; ProPred 
http://www.imtech.res.in/raghava/propred/; and SVMHC, http://abi.inf.uni-
tuebingen.de/Services/SVMHC). 
2.4. Generation of Ser
419
P-ENOA-specific CD4
+
 T cells. Peptide–specific CD4+ T cells were 
obtained after two rounds of in vitro stimulation of PBMCs from a HLA-DRB1*08:01 healthy 
donor. Briefly, PBMCs were cultured in 24-well plates in RPMI 1640 medium plus 10% heat-
inactivated certified FBS (both from Invitrogen Life Technologies, Italy) in the presence of the 
Ser
419
P-ENOA synthetic peptide (
412
RIEEELGSpKAKFAGRNFRN
430
) (10 µg/ml; China Peptides 
Co., China). Recombinant IL-2 (10U/ml) (Proleukin, Novartis Farma, Italy) was added on day 5, 
and replenished every 3-4 days. T cells were re-stimulated for two rounds with irradiated 
autologous PBMCs pulsed with Ser
419
P-ENOA, and T cells were then cloned for limited dilution, as 
previously described [15]. Long term CD4
+
 T cell clones were re-stimulated every 10-14 days with 
irradiated feeder cells. 
2.5. Generation of HLA-DRB1*08:01 EBV-B cell lines. To obtain EBV-transformed 
lymphoblastoid B cell lines (EBV-B cells), PBMCs from a HLA-DRB1*08:01 healthy donor were 
incubated overnight with the supernatant from the EBV-producing marmoset cell line B95.8 (kindly 
provided by Dr. Ada Funaro, University of Turin), and subsequently expanded in complete RPMI 
1640 medium plus 15% heat-inactivated certified FBS in the presence of irradiated allogeneic 
feeder cells. 
2.6. T cell proliferation assay. To assess specific peptide recognition, 2 x 10
4
 cells per well were 
cultured in flat bottomed 96-well plates in RPMI 1640 medium plus 4% heat-inactivated certified 
FBS, 10:1 with autologous irradiated EBV-B cells that had been pulsed overnight with 20 µg/ml 
Ser
419
P-ENOA or the corresponding unphosphorylated form. After 2 days, 1 µCi of [methyl-3H] 
thymidine (
3
HTdR, 25 Ci/mmol) (PerkinElmer Life Sciences, Belgium) was added to each well, and 
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incubated for 18 h. Cells were collected using a CELL Harvester (PerkinElmer Life Sciences) in 
UNIfilter plates, and 
3
HTdR uptake was quantified (TopCount Microplates Scintillation Counter; 
PerkinElmer Life Sciences). All tests were performed in quadruplicate. In some assays growing 
amounts of peptides were used for pulsing EBV-B cells (2, 20 and 200 µg/ml, respectively). 
2.7. Statistical analysis. The allelic frequencies were derived from the direct count of genes. The 
Pearson’s chi-squared test or Fisher’s exact test were used to compare observed allele frequencies, 
as appropriate. Differences were considered statistically significant when p<0.05. Odds ratios (OR) 
were used to estimate the measure of relative risk (CI 95%). The Student’s t-test, calculated using 
Graph-Pad Software Inc. (Version 5, San Diego, CA, USA), was used to evaluate the differences in 
proliferation of CD4
+
 T cell clones. 
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3. Results 
3.1. HLA-DRB1 allelic frequencies in PDAC patients and production of autoantibodies to 
ENO1,2.  
The presence of circulating autoantibodies to the PDAC-associated ENOA1,2 isoforms was 
assessed by 2-DE WB in 113 PDAC patient sera, using CF-PAC-1 cell lysates as source of antigen. 
The HLA-DRB1 allelic frequencies of the same patients were in parallel analyzed with low 
resolution methods. In our cohort, out of 113 patients, 104 were evaluable for ENOA1,2 reactivity 
and 36 of them (35%) were positive, while 68 patients were negative for the presence of ENOA1,2 
autoantibodies (Supplementary Table 1). HLA-DRB1*08 allelic frequency was significantly higher 
(8%, 6/72 alleles) in patients with autoantibodies to ENOA1,2 (ENOA1,2
+
) than in healthy controls 
(3%, 15,648/521,602 alleles; p=0.0112; OR= 2.8141 [1.2199-6.4918]). Moreover HLA-DRB1*08 
allelic frequency was higher in ENOA1,2
+
 patients respect those lacking these autoantibodies 
(ENOA1,2
-
) (2%, 3/136 alleles) (Figure 1). Even if borderline significant (p=0.067) due to the 
small sample size, this trend prompt us to hypothesize a correlation between ENOA1,2 
autoantibody production and a better presentation of phosphorylated-Ser
419
ENOA by the HLA-DR8 
molecule. 
3.2. Prediction of possible HLA ligands of the ENOA C-terminus.  
High resolution typing of HLA-DRB1*08 PDAC patients (n=9) showed that 89% of patients were 
HLA-DRB1*08:01 or *08:04 (n=8/9; relative frequencies: 67% and 22%, respectively), 
(Supplementary Table 2), in line with the results observed in healthy controls from the Caucasian 
population (71% and 12%, respectively [16]). Based on this observation, we employed 
bioinformatics tool IEDB (http://tools.immuneepitope.org/mhcii/) to predict possible HLA-DRB1 
ligands of the C-terminus region of ENOA
410-432
,
 
which contains Ser
419
 from the HLA-DRB1*08:01 
or *08:04 alleles (Table 1). Notably, we confirmed that DRB1*08:01 and *08:04, along with 
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DRB1*13:01, were the alleles that had the highest affinity for the C-terminus of ENOA
411-431
 
(Table 1). The predicted binding core in this portion of ENOA is the 9mer 
417
LGSKAKFAG
425
, 
where the primary anchor residue is Leu
417
 (P1), and the phosphorylable residue Ser
419 
is in the 
position P3. It has been demonstrated that the phosphomoiety stabilizes the MHC class II-TCR 
complex, without altering the peptide-binding mode, when it is not present in a primary (P1, P6) or 
secondary anchor (P4, P7, P9)[17]. The 9mer 
417
LGSKAKFAG
425
 was also predicted by other 
publicly available methods (NetMHCII, HLAPred, ProPred and SVMHC), together with additional 
ENOA peptides able to bind to the HLA-DR8 molecule (Supplementary Figure 1). 
3.3. Specific CD4
+
 T cell recognition of the Ser
419
P-ENOA peptide. 
Since the four N-terminal residues in positions P4 to P1 of the binding core of a tumor-associated 
MHC class II-restricted phosphopeptide include structural determinants required for TCR 
recognition [17], in order to perform functional studies, we synthesized a Ser
419
P-ENOA peptide 
(
412
RIEEELGSpKAKFAGRNFRN
430
), along with the corresponding unphosphorylated ENOA 
peptide (
412
RIEEELGSKAKFAGRNFRN
430
), which was 10 amino acids longer than the predicted 
9-mer HLA-DRB1*08 binding peptide (
417
LGSKAKFAG
425
).  
PBMCs from a HLA-DRB1*08:01 healthy donor were repeatedly stimulated in vitro with the 
Ser
419
P-ENOA peptide. In long-term CD4
+
 T cell cultures, 21 CD4
+
 T cell clones were selected, 
which were able to proliferate in response to the autologous EBV-B cells pulsed with Ser
419
P-
ENOA (data not shown). Five of these CD4
+
 T cell clones showed a significant proliferative 
response to the Ser
419
P-ENOA, which was higher than that induced by the unphosphorylated 
peptide (Figure 2A). Moreover, using increasing concentrations of the Ser
419
P-ENOA peptide for 
pulsing of autologous EBV-B cells, a dose-dependent proliferation of CD4
+
 T cell clones was 
observed (Figure 2B). These data indicate that CD4
+
 T cells specifically recognize Ser
419
P-ENOA, 
demonstrating that the phosphorylated serine residue is a critical determinant of recognition. 
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4. Discussion 
In this study we demonstrate, for the first time, an association between the presence of the HLA-
DRB1*08 allele and the production of autoantibodies against a phosphorylated epitope of a specific 
TAA, namely ENOA. We have shown that HLA-DRB1*08 allele is more frequent in PDAC 
patients with autoantibodies against Ser
419
P-ENOA than healthy controls or patients lacking these 
autoantibodies. Notably, an ENOA-derived peptide containing Ser
419
 was bioinformatically-
predicted to bind with high affinity to the HLA-DR8 molecule coded by HLA-DRB1*08:01 or 
*08:04 alleles. The Ser
419
P-ENOA peptide was able to induce proliferation of HLA-DR8-restricted 
CD4
+
 T cell clones due to the phosphate moiety of the peptide, presented in the context of HLA-
DRB1*08, to a greater extent than the corresponding unphosphorylated peptide. 
We have previously reported that two Ser
419
 phosphorylated isoforms of the glycolytic enzyme 
ENOA (ENOA1,2) elicit the production of autoantibodies in a subset of PDAC patients, who show 
a more favorable clinical outcome [3, 6, 7, 18]. Several TAAs induce the production of IgG 
autoantibodies in cancer patients, by means of an integrated immune response triggered by CD4
+
 T 
cells, CD8
+
 T cells and B cells. TAAs released by tumor cells are captured from APCs, processed 
and presented by either MHC class I or class II molecules for priming and activation of CD8
+
 and 
CD4
+
 T cells, respectively. Activated CD4
+
 T cells, through the secretion of appropriate cytokines, 
trigger B cells to produce IgG against the same TAA, and leads to differentiation of CD8
+
 T cells 
into TAA-specific CTL [19, 20]. ENOA in PDAC can elicit a coordinated CD4
+
 and CD8
+
 T cell 
response both in vitro and in vivo and, in PDAC patients, the production of anti-ENOA IgG 
correlates with the ability of T cells to be activated in response to ENOA [21]. Ex vivo analysis of 
pancreatic cancer-infiltrating T lymphocytes has revealed that ENOA Th1/Th17 effector cells and T 
reg cells tend to accumulate in tumor tissue [15].  
The prognostic value of Ser
419
P-ENOA-autoantibodies, together with the ability of ENOA to induce 
a specific CD4
+
 T cell response, prompted us to investigate whether, in PDAC patients, the ability 
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to produce autoantibodies against Ser
419
P-ENOA is associated with the presence of specific HLA-
DRB1 alleles. Here we show that the allelic frequency of HLA-DR8, coded by the HLA-
DRB1*08:01 or *08:04 alleles, was significantly higher in PDAC patients with ENOA1,2 
autoantibodies than in patients without autoantibodies or in healthy controls, suggesting a 
preferential presentation of Ser
419
P-ENOA peptides by HLA-DR8. 
The ENOA sequence shows several bioinformatically-predicted HLA-DR8 binding peptides, and 
the ability of ENOA-derived peptides to bind HLA-DR8 has also been previously reported in 
primary biliary cirrhosis and in oral squamous cell carcinoma [22, 23, 24, 25]. Interestingly, the C-
terminus region of ENOA that contains Ser
419
 was predicted to bind with high affinity to the HLA-
DR8 molecule, with the residue Ser
419
 in position P3 of the HLA-DR8 binding peptide. As the 
phosphomoiety stabilizes the MHC class II-TCR complex, without altering the peptide-binding 
mode when it is not present in a primary or secondary anchor [17], the same peptide is likely to be 
able to bind HLA-DR8 when the phosphorylation event occurs. This Ser
419 
phosphorylated peptide 
was synthesized according to the molecular basis for phosphopeptide MHC class II presentation, 
recently resolved by crystallographic analysis, and was able to activate specific CD4
+
 T cell clones 
derived from a HLA-DRB1*08:01 donor. Synthetic peptides were chosen as Ser
419
-ENOA 
phosphorylation seems to be pancreatic specific [3, 18], suggesting that ENOA would not be 
properly phosphorylated when expressed into EBV-transformed cells. As reported in previous 
studies in which T cells could discriminate phosphopeptides from their unphosphorylated 
counterparts [9, 10, 11, 12], the HLA-DR8-restricted CD4
+
 T cell clones were specific for the 
phosphate moiety of the ENOA-derived peptide presented in the context of HLA-DR8. The crystal 
structure of phosphopeptide–MHC complexes shows, in fact, that the phosphomoiety is exposed to 
the TCR, suggesting a direct interaction between the phosphorylated residue and the TCR [8, 17, 
26].  
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The identification of a CD4
+
 T cell clone able to proliferate and produce IFN-γ after stimulation 
with ENOA-derived phosphopeptide strongly supports the hypothesis that the preferential 
production of IgG antibodies to Ser
419
P-ENOA in HLA-DR8 patients is critically controlled by the 
activation of CD4
+
 helper T cells that recognize the phosphopeptide in the context of HLA-DR8. It 
is likely that this ENOA-derived phosphopeptide is displayed by the HLA-DRB1*08 allele on the 
surface of B cells or other APCs and thus activates specific CD4
+
 T helper cells, which in turn help 
B cells to produce antibodies against this tumor-associated ENOA-derived phosphopeptide. 
Although the frequency of the HLA-DRB1*08 allele is relatively low in Caucasian populations, its 
presence could be considered as a genetic factor that influences the production of autoantibodies 
against ENOA1,2. 
In conclusion, our results suggest that Ser
-419
P-ENOA peptide–MHC complexes can trigger T-cell 
signaling and induce an anti-tumor immune response, thus portraying ENOA not only as a 
diagnostic tool, but also as a promising candidate for PDAC immunotherapy. DNA-based 
vaccination against human ENOA is able to significantly prolong the median life expectancy of 
mice that spontaneously develop PDAC, by inducing both a humoral and cellular response  [27]. 
Based on the findings described in this study, together with the prognostic value of Ser
419
P-ENOA-
autoantibodies, it can be speculated that the presence of HLA-DRB8 in PDAC patients can be an 
indicator of a better response to chemotherapy, as well as a potential marker for selecting candidates 
for DNA-based ENOA vaccination. 
 
Acknowledgements 
We would like to thank Dr. Radhika Srinivasan for critically reading the manuscript and Dr. 
Valentina Bardina for technical help. This work was partly supported by grants from the European 
Community Seventh Framework Program (EPC-TM-Net, no. 256974); Associazione Italiana 
Ricerca sul Cancro 5 x mille (no. 12182) and IG (nos. 5548 and 11643); Regione Piemonte: Ricerca 
14 
 
Industriale e Sviluppo Precompetitivo (ONCOPROT), Ricerca Industriale “Converging 
Technologies” (BIOTHER); Ministero dell’Istruzione e della Ricerca (MIUR), Progetti di Rilevante 
Interesse Nazionale (PRIN 2009); University of Turin: Progetti di Ateneo 2011 (grant Rethe-
ORTO11RKTW), 60% 2012. P.J.B.H. was supported by an ERACOL fellowship. 
References 
[1] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277-300. 
[2] Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-17. 
[3] Tomaino B, Cappello P, Capello M, et al. Circulating autoantibodies to phosphorylated 
alpha-enolase are a hallmark of pancreatic cancer. J Proteome Res. 2011;10:105-12. 
[4] Capello M, Ferri-Borgogno S, Cappello P, Novelli F. alpha-Enolase: a promising therapeutic 
and diagnostic tumor target. FEBS J. 2011;278:1064-74. 
[5] Ceruti P, Principe M, Capello M, Cappello P, Novelli F. Three are better than one: 
plasminogen receptors as cancer theranostic targets. Exp Hematol Oncol. 2013;2:12. 
[6] Chiriaco MS, Primiceri E, Monteduro AG, et al. Towards pancreatic cancer diagnosis using 
EIS biochips. Lab Chip. 2013;13:730-4. 
[7] Bianco M, Aloisi A, Arima V, et al. Quartz crystal microbalance with dissipation (QCM-D) 
as tool to exploit antigen-antibody interactions in pancreatic ductal adenocarcinomadetection. 
Biosens Bioelectron. 2013;42:646-52. 
[8] Petersen J, Purcell AW, Rossjohn J. Post-translationally modified T cell epitopes: immune 
recognition and immunotherapy. J Mol Med (Berl). 2009;87:1045-51. 
[9] Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, Engelhard VH. 
Phosphorylated peptides are naturally processed and presented by major histocompatibility complex 
class I molecules in vivo. J Exp Med. 2000;192:1755-62. 
[10] Zarling AL, Polefrone JM, Evans AM, et al. Identification of class I MHC-associated 
phosphopeptides as targets for cancer immunotherapy. Proc Natl Acad Sci U S A. 2006;103:14889-
94. 
[11] Depontieu FR, Qian J, Zarling AL, et al. Identification of tumor-associated, MHC class II-
restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci U S A. 
2009;106:12073-8. 
[12] Meyer VS, Drews O, Gunder M, Hennenlotter J, Rammensee HG, Stevanovic S. 
Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I 
phospholigands. J Proteome Res. 2009;8:3666-74. 
15 
 
[13] Amoroso A, Ferrero, N. M.,  Rendine, S.  Sacchi, N. Le caratteristiche HLA della 
popolazione italiana: analisi di 370.000 volontari iscritti all'IBMDR. Analysis 2010;1/2:23-104. 
[14] Bui HH, Sidney J, Peters B, et al. Automated generation and evaluation of specific MHC 
binding predictive tools: ARB matrix applications. Immunogenetics. 2005;57:304-14. 
[15] Amedei A, Niccolai E, Benagiano M, et al. Ex vivo analysis of pancreatic cancer-infiltrating 
T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 
effector cell functions. Cancer Immunol Immunother. 2013;62:1249-60. 
[16] Rendine S, Ferrero NM, Sacchi N, Costa C, Pollichieni S, Amoroso A. Estimation of human 
leukocyte antigen class I and class II high-resolution allele and haplotype frequencies in the Italian 
population and comparison with other European populations. Hum Immunol. 2012;73:399-404. 
[17] Li Y, Depontieu FR, Sidney J, et al. Structural basis for the presentation of tumor-associated 
MHC class II-restricted phosphopeptides to CD4+ T cells. J Mol Biol. 2010;399:596-603. 
[18] Zhou W, Capello M, Fredolini C, et al. Mass spectrometry analysis of the post-translational 
modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells. J Proteome Res. 
2010;9:2929-36. 
[19] Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. 
Curr Opin Immunol. 1997;9:709-16. 
[20] Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ 
T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 
2003;421:852-6. 
[21] Cappello P, Tomaino B, Chiarle R, et al. An integrated humoral and cellular response is 
elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated 
antigen. Int J Cancer. 2009;125:639-48. 
[22] Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and 
promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med. 
1993;178:27-47. 
[23] Akisawa N, Maeda T, Iwasaki S, Onishi S. Identification of an autoantibody against alpha-
enolase in primary biliary cirrhosis. J Hepatol. 1997;26:845-51. 
[24] Sato N, Nabeta Y, Kondo H, et al. Human CD8 and CD4 T cell epitopes of epithelial cancer 
antigens. Cancer Chemother Pharmacol. 2000;46 Suppl:S86-90. 
[25] Kondo H, Sahara H, Miyazaki A, et al. Natural antigenic peptides from squamous cell 
carcinoma recognized by autologous HLA-DR8-restricted CD4+ T cells. Jpn J Cancer Res. 
2002;93:917-24. 
16 
 
[26] Mohammed F, Cobbold M, Zarling AL, et al. Phosphorylation-dependent interaction 
between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed 
self. Nat Immunol. 2008;9:1236-43. 
[27] Cappello P, Rolla S, Chiarle R, et al. Vaccination with ENO1 DNA prolongs survival of 
genetically engineered mice with pancreatic cancer. Gastroenterology. 2013;144:1098-106.
17 
 
 
Figure legends 
Figure 1. HLA-DR allelic frequencies in PDAC patients based on ENOA1,2-reactivity, and 
healthy controls. Low resolution HLA-DR typing was performed in PDAC patients, previously 
classified according to ENOA1,2 reactivity (n=104; described in Supplementary Table 1), and 
healthy controls (n=260801). HLA-DR8 was significantly more frequent in PDAC patients with 
autoantibodies to ENOA1,2 than in healthy controls (8% vs. 3%, p=0.0112, allelic frequency) and is 
higher than in PDAC patients lacking these autoantibodies (8% vs. 2%, allelic frequency). 
Figure 2. Specific CD4
+
 T cell recognition of the Ser
419
P-ENOA peptide. A) Proliferation of 
specific CD4
+
 T cell clones against the autologous EBV-B cells that had been pulsed with Ser
419
P-
ENOA or the corresponding unphosphorylated control peptide (Ser
419
ENOA). Symbols on the right 
show the p value relative to the comparison of Ser
419
P-ENOA vs Ser
419
ENOA for each T cell clone. 
B) Proliferation of specific CD4
+
 T cell clones against the autologous EBV-B cells pulsed with 
growing concentrations of Ser
419
P-ENOA (black symbols) or Ser
419
ENOA (white symbols) of two 
CD4
+
 T cell clones from panel A). The p values are: 0.002 at 2 ng/ml, 0.0213 and <0.0001 at 20 
ng/ml, 0.0017 and 0.0003 at 200 ng/ml, respectively. The Stimulation Index (SI) was calculated as 
the ratio between the mean values of cpm (counts per minute) obtained from stimulated cultures, 
and those obtained in the presence of EBV-B cells in medium alone. Background cpm values from 
CD4
+ 
T cell clones in medium alone were always subtracted.  
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